| In Vitro Drug Sensitivity Testing of Fresh Human Samples (NCT05001386) | Hospices Civils de Lyon | 2022-03-01 |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (NCT05088356) | Stanford University | 2021-09-07 |
| Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021) (NCT07445984) | Azienda Ospedaliero-Universitaria di Parma | 2021-07-28 |
| Thrombosomes® in Bleeding Thrombocytopenic Patients Study (NCT04631211) | Cellphire Therapeutics, Inc. | 2021-03-05 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (NCT04717414) | Celgene | 2021-02-25 |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation (NCT04464889) | Medigene AG | 2020-07-02 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders (NCT02663648) | Shandong University | 2016-06-01 |
| Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal (NCT02766153) | Centre Hospitalier Universitaire de Nice | 2016-05-01 |
| PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis (NCT02806375) | St. Petersburg State Pavlov Medical University | 2016-01-01 |
| Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms (NCT02580903) | Odense University Hospital | 2015-02-01 |
| Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis (NCT04631458) | Royal Free Hospital NHS Foundation Trust | 2014-11-12 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (NCT02158858) | Constellation Pharmaceuticals | 2014-07-16 |
| Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 (NCT02320656) | Institut Paoli-Calmettes | 2014-05-01 |
| Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT (NCT03977103) | University Of Perugia | 2014-02-01 |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF (NCT01787552) | Novartis Pharmaceuticals | 2013-05-08 |
| A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving (NCT01684150) | Epizyme, Inc. | 2012-09-01 |
| Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases (NCT01787162) | Medical University of Graz | 2012-07-01 |
| Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies (NCT01413568) | Polyphor Ltd. | 2012-04-01 |
| Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador (NCT05825326) | Sociedad de Lucha Contra el Cáncer del Ecuador | 2012-01-01 |
| Preservation of Ovarian Function After Hematopoietic Cell Transplant (NCT01343368) | Masonic Cancer Center, University of Minnesota | 2011-07-01 |
| Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders (NCT01392989) | Everett Meyer | 2011-03-01 |
| MSC and HSC Coinfusion in Mismatched Minitransplants (NCT01045382) | University of Liege | 2010-07-01 |
| Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (NCT01366612) | Hackensack Meridian Health | 2010-06-16 |
| A Study in Myeloproliferative Disorders (NCT01134120) | Eli Lilly and Company | 2010-04-01 |
| Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry (NCT01144780) | Stanford University | 2009-09-01 |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor (NCT00967343) | Kiadis Pharma | 2009-08-01 |
| STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders (NCT00858572) | Synta Pharmaceuticals Corp. | 2009-03-01 |
| B-Receptor Signaling in Cardiomyopathy (NCT01135849) | Daniel Bernstein | 2008-11-01 |
| Pathogenesis of Hematologic Malignancies (NCT01728402) | OHSU Knight Cancer Institute | 2008-09-01 |
| JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders (NCT00873574) | Assistance Publique - Hôpitaux de Paris | 2008-09-01 |
| A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis (NCT00745550) | S*BIO | 2008-08-01 |
| Investigation of the Cylex® ImmuKnow® Assay (NCT00569842) | Indiana University | 2007-11-01 |
| T-Reg Cell Kinetics, Stem Cell Transplant, REGALE (NCT00578539) | Baylor College of Medicine | 2007-10-01 |
| Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (NCT00852709) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-09-01 |
| Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer (NCT00499668) | Vanderbilt-Ingram Cancer Center | 2007-08-01 |
| A Safety Study of XL019 in Adults With Myelofibrosis (NCT00522574) | Exelixis | 2007-08-01 |
| Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT (NCT01683123) | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | 2007-07-01 |
| Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer (NCT00787761) | Northside Hospital, Inc. | 2007-04-01 |
| Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer (NCT00827099) | Northside Hospital, Inc. | 2006-06-01 |
| A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT00283114) | Seagen Inc. | 2005-11-01 |
| Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) (NCT00361140) | H. Lee Moffitt Cancer Center and Research Institute | 2005-08-01 |
| Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer (NCT00295880) | Masonic Cancer Center, University of Minnesota | 2005-06-01 |
| Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant (NCT00305682) | Masonic Cancer Center, University of Minnesota | 2005-06-01 |
| Pegasys® in Patients With Myeloproliferative Diseases (NCT00452023) | M.D. Anderson Cancer Center | 2005-04-07 |
| TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD (NCT00185796) | Stanford University | 2004-07-01 |
| Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) (NCT00075816) | Medical College of Wisconsin | 2004-01-01 |
| Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies (NCT00943293) | University of Chicago | 2003-05-01 |
| Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias (NCT00276926) | University of Bologna | 2003-03-01 |
| Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders (NCT00186576) | Stanford University | 2001-12-01 |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood (NCT00146055) | University of Michigan Rogel Cancer Center | 2000-03-01 |
| Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies (NCT00038051) | M.D. Anderson Cancer Center | 1999-05-01 |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow (NCT00003838) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-04-15 |
| Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders (NCT00511537) | University of California, San Francisco | 1999-01-01 |
| Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies (NCT00186342) | Stanford University | 1992-09-01 |